P-107 CLINICAL SPECTRUM OF METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PATIENTS WITH ALTERED ANKLE-BRACHIAL INDEX (ABI) AND CARDIOVASCULAR (CV) RISK FACTORS.

Abstract

Conflict of interest: No Introduction and Objectives: MASLD is the most common chronic liver disease (CLD) with a worldwide prevalence of 25%. It is defined as >5% steatosis without any other known liver disease. Cardiovascular disease (CVD) is the most common cause of death in MASLD. Due to its association with atherosclerosis and its coexistence with traditional CV risk factors (i.e. obesity, insulin resistance, diabetes mellitus, dyslipidemia and hypertension). ABI is a simple and non-invasive tool used to diagnose peripheral arterial disease (PAD), an ABI of ≤0.9 is diagnostic of PAD and has shown to be an independent risk factor for CV disease and CV mortality. Currently, borderline ABI (0.91-0.99) is recommended to be considered as a CV risk factor. Aim: To describe the frequency of MASLD and altered ABI in patients with traditional CV risk factors. Patients / Materials and Methods: An observational, descriptive, and cross-sectional study was performed, we included adult patients with CV risk factors (18 to 70 years old). The sociodemographic characteristics, alcohol consumption, drug usage, smoking and anthropometric measurements (height, weight, BMI, waist, hip and neck circumference) were collected. ABI measurement was performed in all patients with a 8 mHz vascular doppler to classify patients as: Normal ABI (1.0-1.4), Altered ABI (≤0.9 or >1.4) and borderline ABI (0.91-0.99). Transient elastography (Fibroscan) was performed to determine steatosis and fibrosis stage. We excluded pregnant women, previously known CV disease, CLD or PAD. Descriptive statistics and comparative analysis were performed using SPSS version 24 software. Results and Discussion: Sixty-eight patients with CV risk factors were included (48 female [70.6%] with a mean age of 47.38 years). Comorbidities were detected as follows: obesity in 52 patients (76.5%); dyslipidemia in 49 patients (72%); diabetes mellitus in 46 patients (67.6%); arterial hypertension in 35 patients (51.5%). Fifty-three patients had normal ABI (77.9%); altered ABI was found in 15 patients (22.1%). Sixty-one patients were found to have steatosis (89.7%), out of which 14 patients had fibrosis (22.9%). Comparison of both groups (altered vs. normal ABI) are presented in Table 1. Conclusions: Patients with traditional CV risk factors showed a high rate of MASLD and similar altered ABI compared to previously described populations.